PMID- 28049246
OWN - NLM
STAT- MEDLINE
DCOM- 20170331
LR  - 20221207
IS  - 1598-6357 (Electronic)
IS  - 1011-8934 (Print)
IS  - 1011-8934 (Linking)
VI  - 32
IP  - 2
DP  - 2017 Feb
TI  - Efficacy and Tolerability of Solifenacin 5 mg Fixed Dose in Korean Children with 
      Newly Diagnosed Idiopathic Overactive Bladder: a Multicenter Prospective Study.
PG  - 329-334
LID - 10.3346/jkms.2017.32.2.329 [doi]
AB  - We investigated the efficacy and tolerability of solifenacin 5 mg fixed dose in 
      children with newly diagnosed idiopathic overactive bladder (OAB). A total of 34 
      children (male/female patients = 16/18) aged under 13 years (mean age: 7.2 +/- 2.3; 
      range: 5-12) who were newly diagnosed with OAB from January 2012 to September 
      2014 were prospectively evaluated with open-label protocol. All patients were 
      treated with solifenacin 5 mg fixed dose once daily for at least 4 weeks. The 
      efficacy and tolerability of solifenacin were evaluated 4, 8, and 12 weeks after 
      the initiation of treatment. The mean voiding frequency during daytime was 
      decreased from 9.4 +/- 3.0 to 6.5 +/- 2.3 times after the 12-week treatment (P < 
      0.001). The mean total OAB symptom score (OABSS) decreased from 7.7 +/- 4.2 to 3.1 
      +/- 3.1 after the 12-week treatment (P < 0.001). The urgency and urgency urinary 
      incontinence (UUI) domains significantly improved from the 12-week treatment, and 
      complete resolution of urgency occurred in 38.9% of patients and the percentage 
      of children with UUI among urgent patients decreased from 79.4% to 57.1%. 
      According to 3-day voiding diaries, the average bladder capacity increased from 
      90.4 +/- 44.4 to 156.2 +/- 67.3 mL (P < 0.001). Drug-induced adverse effects (AEs) 
      were reported in 7 patients (20.6%). Our results indicate that solifenacin 5 mg 
      fixed dose is effective against OAB symptoms, and its tolerability is acceptable 
      without significant AEs in children with OAB.
FAU - Lee, Sang Don
AU  - Lee SD
AUID- ORCID: 0000-0001-9459-3887
AD  - Department of Urology, Pusan National University Yangsan Hospital and Research 
      Institute for Convergence of Biomedical Science and Technology, Yangsan, Korea.
FAU - Chung, Jae Min
AU  - Chung JM
AUID- ORCID: 0000-0003-3593-9643
AD  - Department of Urology, Pusan National University Yangsan Hospital and Research 
      Institute for Convergence of Biomedical Science and Technology, Yangsan, Korea.
AD  - Department of Urology, Kosin University College of Medicine, Busan, Korea.
FAU - Kang, Dong Il
AU  - Kang DI
AUID- ORCID: 0000-0003-2283-4041
AD  - Department of Urology, Inje University Busan Paik Hospital, Busan, Korea.
FAU - Ryu, Dong Soo
AU  - Ryu DS
AUID- ORCID: 0000-0002-7557-0820
AD  - Department of Urology, Samsung Changwon Hospital, Sungkyunkwan University School 
      of Medicine, Changwon, Korea.
FAU - Cho, Won Yeol
AU  - Cho WY
AUID- ORCID: 0000-0001-6640-7872
AD  - Department of Urology, Dong-A University Hospital, Dong-A University, Busan, 
      Korea.
FAU - Park, Sungchan
AU  - Park S
AUID- ORCID: 0000-0002-2337-983X
AD  - Department of Urology, Ulsan University Hospital, University of Ulsan College of 
      Medicine, Ulsan, Korea.
AD  - School of Life Sciences, Ulsan National Institute of Science and Technology, 
      Ulsan, Korea. scpark@amc.seoul.kr.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PL  - Korea (South)
TA  - J Korean Med Sci
JT  - Journal of Korean medical science
JID - 8703518
RN  - 0 (Urological Agents)
RN  - KKA5DLD701 (Solifenacin Succinate)
SB  - IM
MH  - Asian People
MH  - Child
MH  - Child, Preschool
MH  - Drug Tolerance
MH  - Fatigue/etiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Prospective Studies
MH  - Republic of Korea
MH  - Solifenacin Succinate/adverse effects/*therapeutic use
MH  - Treatment Outcome
MH  - Urinary Bladder, Overactive/*drug therapy
MH  - Urinary Incontinence/pathology
MH  - Urination
MH  - Urological Agents/adverse effects/*therapeutic use
MH  - Xerostomia/etiology
PMC - PMC5220001
OTO - NOTNLM
OT  - Anticholinergics
OT  - Child
OT  - Efficacy
OT  - Overactive Bladder
OT  - Tolerability
COIS- The authors have no potential conflicts of interest to disclose.
EDAT- 2017/01/04 06:00
MHDA- 2017/04/01 06:00
PMCR- 2017/02/01
CRDT- 2017/01/04 06:00
PHST- 2016/06/16 00:00 [received]
PHST- 2016/10/16 00:00 [accepted]
PHST- 2017/01/04 06:00 [entrez]
PHST- 2017/01/04 06:00 [pubmed]
PHST- 2017/04/01 06:00 [medline]
PHST- 2017/02/01 00:00 [pmc-release]
AID - 32.329 [pii]
AID - 10.3346/jkms.2017.32.2.329 [doi]
PST - ppublish
SO  - J Korean Med Sci. 2017 Feb;32(2):329-334. doi: 10.3346/jkms.2017.32.2.329.